Chemotherapy for malignant glioma

Expert Review of Neurotherapeutics

Volumn 5, Issue 6 SUPPL., 2005, Pages

  Nicholas, M Kelly ^a,b   Lukas, Rimas ^a   Bangalore, Samir ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Brain Tumor Center   (United States)

Author keywords

Cognitive behavioral effects; End of life issues; Headache; Malignant brain tumor; Medical complications; Seizure

Indexed keywords

4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CELECOXIB; DNA TOPOISOMERASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; FENRETINIDE; GEFITINIB; IMATINIB; IRINOTECAN; ISOTRETINOIN; LOMUSTINE; LONAFARNIB; NITROSOUREA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PLATINUM DERIVATIVE; PROCARBAZINE; TAMOXIFEN; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TIPIFARNIB; UNINDEXED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; BRAIN CANCER; BRAIN TISSUE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOGENESIS; CLINICAL TRIAL; DRUG DNA BINDING; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HUMAN; MORBIDITY; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; DRUG THERAPY; ENZYME INHIBITORS; EXPERT TESTIMONY; GLIOMA; HUMANS;

EID: 27944509497     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.5.6.S41     Document Type: Review

References (86)

1. Rao RD, James CD. Altered molecular pathways in gliomas: an overview of clinically relevant issues. Semin. Oncol. 31, 595-604 (2004).
2. Mischel PS, Cloughesy TF. Targeted molecular therapy of GBM. Brain Pathol. 13, 52-61 (2003).
3. Newton HB. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/AKT/PYEN, mTOR, SHH/PTCH and angiogensisis. Expert Rev. Anticancer Ther. 4, 105-128 (2004).
4. Walker MD, Alexander E, Hunt WE. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic astrocytoma: a co-operative clinical trial. J. Neurosurg. 49333-49343 (1978).
5. Walker MD, Green SB, Byaqr DP et al. Randomized comparison of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N. Engl. J. Med. 303, 1323-1329 (1980).
6. Shapiro W, Green S, Burger P et al. A randomized comparison of intra-arterial versus intravenous BCNU with or without intravenous 5-FU for newly diagnosed patients with malignant glioma. J. Neurosurg. 76, 772-781 (1992).
7. Hochberg F, Pruitt A, Beck D et al. The rationale and methodology for intra-arterial chemotherapy with BCNU as treatment for glioblastoma. J. Neurosurg. 63, 876-880 (1985).
8. Brem H, Piantadosi S, Burger PC et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-Brain Tumor Treatment Group. Lancet 345, 1008-1012 (1995).
9. Westphal M, Hilt DC, Bortey E et al. A Phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 5, 79-88 (2003).
10. Levin VA, Silver P, Hannigan J et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int. J. Radiat. Oncol. Biol. Phys. 18, 321-324 (1990).
11. Kellie SJ, Barbaric D, Koopmans P, Earl J, Carr DJ, de Graaf SS. Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing: a surrogate marker of brain penetration. Cancer 94, 815-820 (2002).
12. Boyle FM, Eller SL, Grossman SA. Penetration of intra-arterially administered vincristine in experimental brain tumor. J. Neurooncol. 6, 300-305 (2004).
13. Prados M, Scott C, Curran WJ Jr, Nelson DF, Leibel S, Kramer S. Procabarzine, lomustine, and vincristsine (PCV) chemotherapy for anaplastic astrocytoma: a retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J. Clin. Oncol. 17, 3389-3395 (1999).
14. Newlands ES, Blackledge GRP, Slack JA et al. Phase I trial of temozolomide (CCRG 81945: M and B 39831: NSC 362856). Br. J. Cancer 65, 287-291 (1992).
15. Bower M, Newlands ES, Blechen NM et al. Multicentre Phase II CRC trial of temozolomide in recurrent or progressive high grade glioma. Cancer Chemother. Pharmacol. 40, 484-488 (1997).
16. Yung WK, Albright RE, Olson J et al. A Phase II study of temozolomide in patients with glioblastoma at first relapse. Br. J. Cancer 83, 588-593 (2000).
17. Yung WK, Prados MD, Yaya-Tur R et al. Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J. Clin. Oncol. 17, 2763-2761 (1999).
18. Stupp R, Dietrich PY, Ostermann S et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol. 20, 3179-3180 (2002).
19. Stupp R, Mason WP, van den Bent WJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005).
20. D'Incalci M, Gitti L, Taverna P et al. Importance of the DNA repair enzyme O6-alkylguanine alkyltransferase (AT) in cancer chemotherapy. Cancer Treat. Rev. 15, 279-292 (1988).
21. Hegi ME, Diserens AC, Gorlin T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997-1003 (2005).
22. Wasserfallen JB, Ostermann S, Pica A et al. Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until death. Cancer 101, 2098-2105 (2004).
23. Korones DN, Benita-Weiss M, Coyle TE et al. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. Cancer 97, 1963-1968 (2003).
24. Chang SM, Lamborn KR, Malec M et al. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblstoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 60, 353-367 (2004).
25. 90Y-biotin radioimmunotherapy and temozolomide. Q. J. Nucl. Med. Mol. Imaging 48, 220-228 (2004).
26. Gururangan S, Cokgor L, Rich JN et al. Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro-oncology 3, 246-250 (2001).
27. Groves MD, Puduvalli VK, Hess KR et al. Phase II trial of temozolomide plus the metalloprotease inhibitor marimistat, in recurrent and progressive glioblastoma multiforme. J. Clin. Oncol. 20, 1383-1388 (2002).
28. Barrie M, Couprie C, Dufour G et al. Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. Ann. Oncol. 16, 1177-1184 (2005).
29. Prados MD, Yung WK, Fine HA et al. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortioum study. Neuro-oncology 6, 33-37 (2004).
30. Chua SL, Rosenthal MA, Wong SS et al. Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. Neuro-oncology 6, 38-43 (2004).
31. Brandes AA, Basso U, Reni M et al. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a Phase II study of the Gruppo Italiano Co-operativo di Neuro-Oncolgica. J. Clin. Oncol. 22, 1598-1604 (2004).
32. Newton H, Turowski R, Stroop T et al. Clinical presentation, diagnosis, and pharmacotherapy of patients with primary brain tumors Ann. Pharmacother. 33, 816-832 (1999).
33. Kumar ARV, Renaudin J, Wilson CB, Boldrey EB, Enot KJ, Levin VA. Procarbazine hydrochloride in the treatment of brain tumors. J. Neurosurg. 40, 365-371 (1974).
34. Franceschi E, Cavallo G, Scopece L et al. Phase II trial of carboplatin and etopopside for patients with recurrent high grade glioma. Br. J. Cancer 91, 1038-1044 (2004).
35. Robins H, Chang SM, Prados MD et al. A Phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-oncology 4, 109-114 (2002).
36. Walker R, Allen J. Cisplatin in the treatment of recurrent childhood brain tumors. J. Clin. Oncol. 6, 62-55 (1985).
37. Packer R, Sutton L, Goldwein J et al. Improved survival with the use of adjuvant chemotherapy in the treatment of medulloblastoma. J. Neurosurg. 74, 433-440 (1991).
38. Newton H, Page M, Junck L, Greenberg HS. Intra-arterial cisplatin for the treatment of malignant gliomas. J. Neurooncol. 7, 39-44 (1989).
39. Prados MD, Schold SC, Fine HA et al. A randomized, double-blind, placebo-controlled, Phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro-oncology 5, 96-103 (2003).
40. Billecke C, Simona C, Ashley M et al. Preclinical development and mechanisutic analysis of the polynuclear platinum compounds of the BBR series by proteomic profiling. Neuro-oncology 6, 330 (2004).
41. Batchelor T, Gilbert MR, Supko JG et al. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro-oncology 6, 21-27 (2004).
42. Friedman HS, Petros WP, Friedman AH et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J. Clin. Oncol. 17, 1516-1525 (1999).
43. RTOG 0420: a Phase II study of radiation therapy plus low dose temozolomide followed by temozolomide plus irinotecan for glioblastoma multiforme.
44. Gupta E, Wang X, Ramirez J et al. Modulation of glucuronidation of SN-38, the active metabolite of mirinotecan, by valproic acid and phenobarbital. Cancer Chemother. Pharmacol. 39, 440-444 (1997).
45. Gelmann EP. Tamoxifen for the treatment of malignancies other than breast or endometrial carcinoma. Semin. Oncol. 24, S1-65, S1-70 (1997).
46. Baltuch GH, Dooley NP, Villemure JG, Vong VW. Protein kinase C and growth regulation of malignant gliomas. Can. J. Neurol. Sci. 22, 264-271 (1995).
47. Couldwell W, Weiss M, DiGiorgio C et al. Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 32, 485-490 (1993).
48. Chamberlain M, Kormanik P. Salvage chemotherapy with tamoxifen for recurrent anaplastic astsrocytoma. Arch. Neurol. 56, 703-708 (1999).
49. Cloughesy TF, Woods RP, Black KL, Couldwell WT, Law RE, Hinton DR. Prolonged treatment with biologic agents for malignant glioma: a case study with high dose tamoxifen. J. Neurooncol. 35, 39-45 (1997).
50. Pollack IF, DaRosso RC, Robertson PL et al. A Phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood. Clin. Cancer Res. 3, 1109-1115 (1997).
51. RTOG-BR 0021. A Phase II trial of conventional radiation therapy plus high dose tamoxifen for supratentorial glioblastoma multiforme (GBM).
52. Wesseling P, Ruiter DJ, Burger PC. Angiogenesis in brain tumors; pathobiological and clinical aspects. J. Neurooncol. 32, 253-265 (1997).
53. Marx GM, Pavlakis N, McCowatt S et al. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J. Neurooncol. 54, 31-38 (2001).
54. Fine HA, Loeffler JS, Kyritsis A et al. A Phase II trial of the anti-angiogenic agent, thalidomide, in patients with recurrent high-grade gliomas. Proc. Am. Soc. Clin. Oncol. 16, (2003) (Abstract 385).
55. Chang SM, Lamborn KR, Malec M et al. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 60, 353-357 (2004).
56. Galustian C, Labarthe MC, Bartlett JB, Dalgleish AG. Thalidomide-derived immunomodulatory drugs as therapeutic agents. Exp. Opin. Biol. Ther. 4, 1963-1967 (2004).
57. Love, JM, Gudis LJ. Vitamin A, differentiation, and cancer. Curr. Opin. Cell Biol. 6, 825-831 (1994).
58. Yung WK, Kyritsis AP, Gleason MJ et al. Treatment of malignant gliomas with high dose 13-cis retinoic acid. Clin. Cancer Res. 2, 1931-1935 (1996).
59. See SJ, Levin VA, Yung WK, Hess KR, Groves MD. 13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme. Neuro-oncology 6, 253-258 (2004).
60. Jaeckle KA, Hess KR, Yung WK et al. Phase II evaluation of temozolomide and 13-cis retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium Study. J. Clin. Oncol. 21, 2305-2311 (2003).
61. Puduvalli VK, Saito Y, Xu R et al. Fenretinide activates caspases and induces apoptosis in gliomas. Clin. Cancer Res. 5, 2230-2235 (1999).
62. Puduvalli VK, Yung WK, Hess KR et al. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J. Clin. Oncol. 22, 4282-4289 (2004).
63. Sohono T, Tofilon PJ, Bruner JM, Owolabi O, Lanf FF. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res. 61, 4375-4381 (2001).
64. Castilla EA, Prayson RA, Kanner AA et al. Cycloxygenase-2 in oligodendroglial neoplasms. Cancer 98, 1465-1472 (2003).
65. Giglio P, Levin VA. Cyclooxygenase-2 inhibitors in glioma therapy. Am. J. Ther. 11, 141-3 (2004).
66. Reardon DA, Quinn JA, Vrendenburgh J et al. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer 103, 329-338 (2005).
67. Rich JN, Reardon DA, Peery T et al. Phase II trial of gefitinib in glioblastoma. J. Clin. Oncol. 22, 133-142 (2004).
68. Vogelbaum MA, Peereboom D, Glen HJ et al. Response rate to single agent therapy with the EGFR tyrosine kinase inhibitor erlotinib in recurrent glioblastoma multiforme: results of a Phase II study. J. Neurooncol. 6, (2004) (Abstract 384).
69. Study JJ. HeR1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. J. Neurooncol. 74, 77-86 (2005).
70. Haas-Kogan D, Prados, MS, Tihan T et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl Cancer Inst. 97, 880-887 (2005).
71. Wen PY, Yung WK, Lamborn K et al. Phase I/II study of imatinib mesylate (STI571) for patients with recurrent malignant gliomas (NABTC 99-08). Neuro-oncology 6, 385a (2004).
72. Cloughsey TF, Kuhn J, Wen P et al. Phase II trial of R11577 (Zarnestra) in patients with recurrent glioma not taking enzyme-inducing anti-epileptic drugs (EIAED): A North American Brain Tumor Consortium (NABTC) report. Proc. Am. Soc. Clin. Oncol. (2002).
73. Dancey JE. Clinical development of mammalian target of rapamycin inhibitors. Hematol. Oncol. Clin. North Am. 16, 1101-1114 (2002).
74. Galanis E, Buckner JC, Maurer MJ et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol. 23, 5294-5304 (2005).
75. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol. 5, 292-302 (2004).
76. Wikstrand CJ, Hale LP, Batra SK et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 55, 3140-3148 (1995).
77. Wikstrand CJ, Cokgor I, Sampson JH, Bigner DD. Monoclonal antibody therapy of human gliomas: current status and future approaches. Cancer Metastasis Rev. 18, 451-464, (1999).
78. Mishima K, Johns TG, Luwor RB et al. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res. 61, 5349-5354 (2001).
79. Brady LW, Miyamoto C, Woo DW et al. Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a Phase II trial. Int. J. Radiat. Oncol. Biol. Phys. 22, 225-230 (1992).
80. Stark-Vance VI. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Proc. World Fed. J. Neurooncology 342, 91 (2005).
81. Greenfield L, Johnson VG, Youle RJ. Mutations in diptheria toxin separate binding from entry and amplify immunotoxin selectivity. Science 238, 536-539 (1987).
82. Debinski W, Obiri N, Powers S et al. A novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin-13 and interleukin-4. J. Biol. Chem. 270, 16775-16780 (1995).
83. Fitzgerald D, Pastan I. Pseudomonas exotoxin and recombinant exotoxins derived from it. Ann. NY Acad. Sci. 685, 740-745 (1993).
84. Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J. Neuro-Oncol. 65, 3-13 (2003)
85. Kunwar S. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing Phase I studies. Acta Neurochir. Suppl. 88, 105-111 (2003).
86. Stevens MS, Newlands ES. From triazines to triazenes to temozolomide. Eur. J. Cancer 29A, 1045-1047 (1993).